返回 
加入收藏
曲美他嗪对高血压性心脏病患者心肌重构和氧化应激水平的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 曲美他嗪对高血压性心脏病患者心肌重构和氧化应激水平的影响 |
| TITLE： | |
| 摘要： | 目的：前瞻性研究曲美他嗪对高血压性心脏病（简称高心病）患者心肌重构和氧化应激水平的影响，为该药用于高心病的临床治疗提供参考。方法：选取我院2014年1月－2016年6月收治的高心病患者82例，根据抽签法随机分为对照组和观察组，各41例。对照组患者给予常规高心病化学药物（降压药、降脂药、降糖药、抗血小板药等）治疗；观察组患者在对照组基础上再给予曲美他嗪20 mg，tid。疗程均为3个月。于治疗前和治疗3个月后，比较两组患者收缩压（SBP）、舒张压（DBP）、纽约心脏病协会（NYHA）心功能分级、左心室射血分数（LVEF）、左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）、左心室重量指数（LVMI）和血清中谷胱甘肽过氧化物酶（GSH-Px）、超氧化物歧化酶（SOD）、丙二醛（MDA）、活性氧（ROS）水平变化，并观察其不良反应发生情况。结果：治疗前，两组患者各指标差异均无统计学意义（P＞0.05）。治疗3个月后，两组患者SBP、DBP较治疗前显著降低（P＜0.01），但两组间差异无统计学意义（P＞0.05）；两组患者NYHA心功能分级较治疗前以及两组间比较差异均无统计学意义（P＞0.05）；观察组LVESD、LVEDD、LVMI较治疗前显著降低（P＜0.05），LVEF较治疗前显著升高（P＜0.05），且观察组LVEDD、LVMI显著低于对照组（P＜0.05）；对照组仅SOD水平较治疗前显著降低，而观察组GSH-Px 、SOD水平较治疗前均显著升高，MDA、ROS水平均显著降低，且观察组MDA、ROS水平显著低于对照组，差异均有统计学意义（P＜0.05）。两组患者均未见明显不良反应事件发生。结论：曲美他嗪可改善高心病患者的心肌重构、降低其氧化应激水平，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To prospectively study the effects of trimetazidine on myocardial remodeling and oxidative stress in patients with hypertensive heart disease （HHD）， in order to provide reference for clinical treatment of HHD. METHODS： Eighty-two HHD patients were selected from our hospital during Jan. 2014-Jul. 2016， and they were divided into control group and observation group by sortition randomization method， with 41 cases in each group. Control group received routine HHD chemical drug （antihypertensive drugs， lipid-lowering drugs， hypoglycemic agents and antiplatelet drugs， etc.） therapy. Observation group was additionally given trimetazidine 20 mg， tid， on the basis of control group. Both groups were treated for 3 months. Before treatment and after 3 months of treatment， SBP， DBP， New York Heart Association （NYHA） cardiac function grade， LVEF， LVESD， LVEDD， LVMI and the levels of GSH-Px， SOD， MDA and ROS were compared between 2 group. The occurrence of ADR was observed in 2 groups. RESULTS： Before treatment， there was no statistical significance in each index between 2 groups （P＞0.05）. After 3 months of treatment， SBP and DBP of 2 groups were decreased significantly compared to before treatment （P＜0.01）； there was no statistical significance between 2 groups （P＞0.05）. There was no statistical significance in NYHA cardiac function grade compared to before treatment or between 2 groups （P＞0.05）. LVESD， LVEDD and LVMI of observation group were decreased significantly compared to before treatment （P＜0.05）； LVEF was increased significantly compared to before treatment （P＜0.05）； LVEDD and LVMI of observation group were significantly lower than control group （P＜0.05）. Compared to before treatment， SOD level of control group was decreased significantly， while the levels of GSH-Px and SOD in observation group were increased significantly； MDA and ROS of observation group were significantly lower than those of control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Trimetazidine can improve cayocardial remodeling and reduce oxidative stress level of HHD patients with good safety. |
| 期刊： | 2018年第29卷第1期 |
| 作者： | 武文君，宣玲，汪朝晖，王廷涛，高兰兰，沙莎 |
| AUTHORS： | WU Wenjun，XUAN Ling，WANG Zhaohui，WANG Tingtao，GAO Lanlan，SHA Sha |
| 关键字： | 曲美他嗪；高血压性心脏病；心肌重构；氧化应激 |
| KEYWORDS： | Trimetazidine； Hypertensive heart disease； Myocardial remodeling； Oxidative stress |
| 阅读数： | 355 次 |
| 本月下载数： | 8 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
